CN108866102B - 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 - Google Patents
一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 Download PDFInfo
- Publication number
- CN108866102B CN108866102B CN201810635308.1A CN201810635308A CN108866102B CN 108866102 B CN108866102 B CN 108866102B CN 201810635308 A CN201810635308 A CN 201810635308A CN 108866102 B CN108866102 B CN 108866102B
- Authority
- CN
- China
- Prior art keywords
- mouse
- guide rna
- gene
- adgrv1
- y6236fsx1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101100434541 Mus musculus Adgrv1 gene Proteins 0.000 title claims abstract description 30
- 238000010171 animal model Methods 0.000 title claims abstract description 18
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 108091033409 CRISPR Proteins 0.000 claims abstract description 36
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 29
- 108020004414 DNA Proteins 0.000 claims abstract description 28
- 230000008439 repair process Effects 0.000 claims abstract description 23
- 230000035772 mutation Effects 0.000 claims abstract description 16
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 11
- 235000013601 eggs Nutrition 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 230000013011 mating Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 11
- 208000016354 hearing loss disease Diseases 0.000 description 8
- 206010011878 Deafness Diseases 0.000 description 7
- 208000014769 Usher Syndromes Diseases 0.000 description 6
- 102100036799 Adhesion G-protein coupled receptor V1 Human genes 0.000 description 4
- 101710096099 Adhesion G-protein coupled receptor V1 Proteins 0.000 description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
- 231100000895 deafness Toxicity 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 230000001720 vestibular Effects 0.000 description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 238000010453 CRISPR/Cas method Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010011882 Deafness congenital Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- 241000203069 Archaea Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000008616 Usher syndrome type 1 Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008140 language development Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,步骤是(1)设计并选择合适的靶向小鼠Adgrv1基因的Guide RNA及修复模板DNA;(2)体外合成Cas9 mRNA、Guide RNA和修复模板DNA;(3)将Guide RNA、Cas9 mRNA和修复模板DNA等摩尔比共同配制成注射样品对受精卵注射;(4)对获得的F0代小鼠进行鉴定;(5)阳性F0代小鼠传代及F1代小鼠的获得与鉴定。本方法可以成功获得与人类中Y6244fsX1致病突变对应的Adgrv1基因Y6236fsX1突变小鼠模型,为研究人类中Y6244fsX1致病突变的相关因素和诊断治疗提供了基础。
Description
技术领域
本发明属于利用基因修饰技术制作基因突变动物模型技术领域,具体涉及一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法。
背景技术
CRISPR/Cas(Clustered Regularly Interspaced Shot Palindromic repeats/CRISPR-associated)系统是原核生物中一种抵抗外源基因侵入的获得性免疫系统,在细菌和古生菌中CRISPR系统整合侵入宿主的噬菌体或者质粒DNA片段到CRISPR位点,然后通过相应的CRISPR RNAs(cr RNAs)引导Cas核酸内切酶对外源DNA序列进行切割,从而抵抗病毒或者噬菌体的入侵。CRISPR/Cas系统分为3种类型(TypeⅠ、TypeⅡ和TypeⅢ),其中TypeⅡ系统因其简单、高效以及功能多样化等优点,自2013在哺乳动物细胞中成功实现基因编辑后,现已被广泛用于多种模式生物的基因组修饰技术应用中。Ⅱ型系统可以通过crRNA的引导利用单个Cas9核酸酶对DNA靶位点进行精确充分地切割。CRISPR/Cas9系统相关载体构建简单快速,便于操作,实验周期较短,且广泛适用于多个物种。在基因编辑的过程中,CRISPR/Cas9系统需要一段特殊的引导RNA,即sgRNA(single guide RNA),sgRNA的序列选择限制性较小,只需要基因组序列中出现PAM(NGG)区即可。在sgRNA的引导下,Cas9蛋白可以对基因组实现定点切割,引起DNA双链断裂,继而引发细胞的自主修复,修复的过程可以是随机的片段缺失或插入,也可以利用特定的模板修复,从而实现对基因组的永久性修饰。
Usher综合征(Usher syndrome,USH)是一种能够引起视觉和听觉双重感官障碍的遗传性疾病,在目前已知的超过50种的视力下降合并听力受损的综合征中,以Usher综合征最为常见,该病的全球发病率为1/6000~1/10000。USH为常染色体隐性遗传病,其特征表现为视网膜色素变性(retinitis pigmentosa,RP)和感音神经性耳聋(sensorineuralhearing loss,SNHL)。USH在临床上分为3种类型,都存在因视网膜色素变性而引起的进行性视力下降,区别在于听力和前庭功能的变现各不相同。其中USH1型最为严重,临床表现有先天性耳聋、严重的听力损失,并因听力障碍导致的语言发育迟缓;此类患者还经常伴有前庭功能障碍,患儿学会独立行走的时间较同龄儿童晚。USH2型患者听力损失较轻,为中到重度耳聋,但前庭功能正常。USH3型以渐进性听力损失为特点,伴随不同程度的前庭功能失调。此外,部分Usher综合征患者还可能伴有智力衰退,嗅觉丧失,癫痫等神经系统病变。
ADGRV1是属于黏附受体亚家族(Adhesion receptor)的一种G蛋白偶联受体(GPCR),是听纤毛踝连接(Ankle-link)的重要组成成分,在听纤毛形成过程中起到重要的作用。ADGRV1是目前已知最大的GPCR蛋白,其mRNA经可变剪切产生不同的蛋白亚型。人ADGRV1 Y6244fsX1突变引起USH2综合征,临床表现为先天性耳聋和渐进性色素性视网膜炎,严重影响患者日常交流与工作学习等。目前对于ADGRV1突变致聋机制尚不明确,因此也缺乏有效的治疗手段。在小鼠中模拟人ADGRV1 Y6244fsX1突变,构建Adgrv1基因Y6236fsX1突变小鼠模型,对ADGRV1突变致聋机制进行深入探讨,以及利用这一模型进行药物筛选,具有重要的临床意义。但检索发现目前虽有Adgrv1基因敲除小鼠,没有仿真模拟人相关耳聋突变的小鼠模型,因此建立一种构建Adgrv1基因Y6236fsX1突变动物模型的方法意义重大。
发明内容
本发明的目的是提供一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法。
本发明所述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,步骤是:
(1)在小鼠Adgrv1基因89号外显子上6236位点Tyrosine附近设计合适的GuideRNA;其中引物Guide RNA target site1的核苷酸序列如SEQ ID NO.1所示,引物Guide RNAtarget site2的核苷酸序列如SEQ ID NO.2所示;设计合适的修复模板DNA以产生Y6236fsX1突变;其中修复模板DNA的核苷酸序列如SEQ ID NO.3所示;
(2)体外合成Guide RNA、Cas9 mRNA与修复模板DNA;
(3)将合成后的Guide RNA、Cas9 mRNA与修复模板DNA等摩尔比共同配制成100ul注射样品,并将样品注射到取自C57BL/6J母鼠受精卵的雄原核中,培养恢复后移植入假孕受体小鼠,等待获得的F0代小鼠;
(4)利用PCR反应体系对获得的F0代小鼠进行鉴定;
(5)将阳性F0代小鼠与野生型C57BL/6J交配获得F1代小鼠,筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
上所述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法中:步骤(2)所述Guide RNA、Cas9 mRNA及修复模板DNA体外合成由生工生物工程(上海)股份有限公司完成。
上述基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法中:步骤(4)所述PCR反应体系的引物为GPR98-test-F3和GPR98-test-R3;其中GPR98-test-F3的核苷酸序列如SEQ ID NO.4所示,GPR98-test-R3的核苷酸序列如SEQ ID NO.5所示。
本发明公开的基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法能够成功获得与人类中Y6244fsX1致病突变对应的Adgrv1基因Y6236fsX1突变小鼠模型。方法中涉及的设计并挑选合适的靶向小鼠Adgrv1基因的Guide RNA,难点在于寻找6236位Tyrosine附近合适的Guide RNA靶点以实现能够模拟人类Y6244fsX1突变的效果。本发明的构建方法为获得模拟人类Adgrv1基因Y6244fsX1致病突变的小鼠模型提供了便利,为研究人类中Y6244fsX1致病突变的相关因素和诊断治疗提供了基础。
附图说明
图1、Adgrv1基因Y6236fsX1突变小鼠构建策略图及基因鉴定引物设计。
图2、F0代阳性小鼠PCR产物测序图谱比对结果。
具体实施方式
如下实施例使用的Taq酶及PCR相关试剂购自TaKaRa公司。化学试剂主要购自Sigma和上海化学试剂公司。胶回收Kit,质粒抽提Kit购于Qiagen公司。修复模板DNA和RNA合成自生工生物工程(上海)股份有限公司。引物合成自英潍捷基(上海)贸易有限公司。
实施例1:基于CRISPR/Cas9技术构建Adgrv1基因Y6236fsX1突变动物模型的构建方法通过以下步骤实现:
(1)靶向小鼠Adgrv1基因的Guide RNA及修复模板DNA的选择和设计
设计Adgrv1基因Y6236fsX1突变小鼠构建策略,如图1所示。
根据构建策略,在Adgrv1基因相应的位置设计合适的Guide RNA,并订购相应的修复模板DNA,其中Guide RNA target site1的核苷酸序列如SEQ ID NO.1所示,Guide RNAtarget site2的核苷酸序列如SEQ ID NO.2所示,修复模板DNA的核苷酸序列如SEQ IDNO.3所示,具体序列如下:
(2)体外合成Guide RNA、Cas9 mRNA和修复模板DNA
Guide RNA、Cas9 mRNA和修复模板DNA由生工生物工程(上海)股份有限公司合成。
(3)受精卵显微注射制备F0代小鼠
1)单细胞受精卵的获得
小鼠超排:第一天,为C57BL/6J小鼠腹腔注射马绒毛膜促性腺激素5IU/只,46-48小时后注射人绒毛膜促性腺激素,注射完人绒毛膜促性腺激素后将2只雌鼠与单放雄鼠1只合笼。第四天上午检栓,见栓的记为0.5天。
获取受精卵:将见栓0.5天后的小鼠脱颈处死,取出输卵管,在解剖镜下小心取出成团的卵子并用透明质酸酶消化,挑取形态饱满且胞质均匀的胚胎放置于M16培养液中培养。
2)显微注射受精卵
将挑选后的受精卵转移入M2条带中依次排列(30-50枚左右)。提前将Guide RNA、Cas9 mRNA及修复模板DNA等摩尔比共同配制成100ul注射样品,待注射管刺入受精卵后匀速将样品注入,见到胞质松散后迅速退针。注射结束后,将受精卵移入M16培养液中,并于37℃、5%二氧化碳培养箱中恢复0.5-1小时。将注射后的受精卵移植到E0.5天假孕小鼠体内。
移植后大约19-21天生出F0代小鼠。
(4)利用PCR反应体系对获得的F0代小鼠进行鉴定
1)F0代小鼠基因组制备
F0代小鼠出生14天剪取鼠尾0.3cm,加400μl裂解液及40μl蛋白酶K(10mg/ml),56℃消化过夜。离心取上清,两倍体积无水乙醇沉淀,75%乙醇洗涤,稍晾干后溶解于100μl纯水中,50℃烘箱助溶1小时。
2)F0代小鼠基因型鉴定
以制取的F0代小鼠基因组为模板使用TaKaRa Lataq扩增鉴定片段,引物为GPR98-test-F3和GPR98-test-R3,如图1所示,可扩增出0.8kb条带。其中,GPR98-test-F3的核苷酸序列如SEQ ID NO.4所示,GPR98-test-R3的核苷酸序列如SEQ ID NO.5所示。
GPR98-test-F3:5′-ATCATAGCAATCTGCGTGTGACTCTGA-3′
GPR98-test-R3:5′-ACACTTTGGCAATGTTAGTTGCTTCTGA-3′
反应条件为94℃5min变性后,94℃40s,60℃30s,72℃1min,进行34个循环,72℃延伸2min,PCR体系参见TaKaRa说明书。
1%琼脂糖凝胶电泳后割胶回收0.8kb条带,分别连接pGEM-T载体(Promega),转化,每个平板挑取6个单克隆测序鉴定,引物为GPR98-test-F3。测序结果显示有19bp碱基缺失,如图2所示。
(5)将阳性F0代小鼠与野生型C57BL/6J交配获得F1代小鼠,筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
阳性F0代小鼠在8周龄左右性成熟后和野生型C57BL/6J回交进行配繁,得到F1代小鼠。同F0代相似,待小鼠出生14天后,剪尾进行PCR鉴定,得到5只F1代杂合子。
筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠。
序列表
<110> 山东大学
<120> 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法
<141> 2018-6-9
<160> 5
<170> PatentIn Version 3.5
<210> 1
<211> 20
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(20)
<223> Guide RNA target site1的核苷酸序列
<400> 1
ttcttctgga ggttatggcc 20
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(20)
<223> Guide RNA target site2的核苷酸序列
<400> 2
tcatcggcta tcagggaccc 20
<210> 3
<211> 98
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(98)
<223> 修复模板DNA的核苷酸序列
<400> 3
tttgaagaca agtccccaga atggtgcctc attcccttct tctggaggtt agccgatgaa 60
gagtcccagg agtttgatga cctgatattt gcattaaa 98
<210> 4
<211> 27
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(27)
<223> 引物GPR98-test-F3的核苷酸序列
<400> 4
atcatagcaa tctgcgtgtg actctga 27
<210> 5
<211> 28
<212> DNA
<213> 人工序列
<220>
<221> 小鼠
<222>(1)…(28)
<223> 引物GPR98-test-R3的核苷酸序列
<400> 5
acactttggc aatgttagtt gcttctga 28
Claims (1)
1.一种基于CRISPR/Cas9技术的Adgrv1基因Y6236fsX1突变动物模型的构建方法,步骤是:
(1)设计合适的Guide RNA;设计合适的修复模板DNA以产生Y6236fsX1突变;
(2)体外合成Guide RNA、Cas9 mRNA和修复模板DNA;
(3)将Guide RNA、Cas9 mRNA与修复模板DNA等摩尔比共同配制成100μl注射样品,并将样品注射到取自C57BL/6J母鼠受精卵的雄原核中,培养恢复后移植入假孕受体小鼠,等待获得的F0代小鼠;
(4)利用PCR反应体系对获得的F0代小鼠进行鉴定;
(5)将阳性F0代小鼠与野生型C57BL/6J交配获得F1代小鼠,筛选出的阳性F1代小鼠即为Adgrv1基因Y6236fsX1突变动物模型小鼠;
其特征在于:
步骤(1)所述设计合适的Guide RNA的策略是:在小鼠Adgrv1基因89号外显子上6236位点Tyrosine附近设计Guide RNA;其中Guide RNA target site1的核苷酸序列如SEQ IDNO.1所示,Guide RNA target site2的核苷酸序列如SEQ ID NO.2所示;设计合适的修复模板DNA的策略是:修复模板DNA的核苷酸序列如SEQ ID NO.3所示;
步骤(4)所述PCR反应体系的引物为GPR98-test-F3和GPR98-test-R3;其中GPR98-test-F3的核苷酸序列如SEQ ID NO.4所示,GPR98-test-R3的核苷酸序列如SEQ ID NO.5所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810635308.1A CN108866102B (zh) | 2018-06-20 | 2018-06-20 | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810635308.1A CN108866102B (zh) | 2018-06-20 | 2018-06-20 | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108866102A CN108866102A (zh) | 2018-11-23 |
CN108866102B true CN108866102B (zh) | 2021-11-16 |
Family
ID=64339662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810635308.1A Active CN108866102B (zh) | 2018-06-20 | 2018-06-20 | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108866102B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109679953B (zh) * | 2018-12-28 | 2022-08-16 | 广州赛业百沐生物科技有限公司 | 利用CRISPR-Cas9系统制得基因点突变动物模型胚胎的靶序列组、载体和方法 |
CN111778246B (zh) * | 2020-06-16 | 2022-04-19 | 首都医科大学附属北京同仁医院 | Sdk2基因突变小鼠模型构建方法及其应用 |
CN112005968A (zh) * | 2020-09-02 | 2020-12-01 | 南京农业大学 | 半乳糖基转移酶GalT基因点突变小鼠模型的构建方法及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106929533A (zh) * | 2017-03-10 | 2017-07-07 | 上海交通大学医学院附属新华医院 | Kars基因点突变小鼠模型的构建方法及其应用 |
CN107475300A (zh) * | 2017-09-18 | 2017-12-15 | 上海市同济医院 | Ifit3‑eKO1基因敲除小鼠动物模型的构建方法和应用 |
WO2018045727A1 (zh) * | 2016-09-06 | 2018-03-15 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
-
2018
- 2018-06-20 CN CN201810635308.1A patent/CN108866102B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018045727A1 (zh) * | 2016-09-06 | 2018-03-15 | 陕西慧康生物科技有限责任公司 | 粘多糖贮积症ii型动物模型的构建方法及应用 |
CN106929533A (zh) * | 2017-03-10 | 2017-07-07 | 上海交通大学医学院附属新华医院 | Kars基因点突变小鼠模型的构建方法及其应用 |
CN107475300A (zh) * | 2017-09-18 | 2017-12-15 | 上海市同济医院 | Ifit3‑eKO1基因敲除小鼠动物模型的构建方法和应用 |
Non-Patent Citations (1)
Title |
---|
Constitutive Gαi Coupling Activity of Very Large G Protein-coupled Receptor 1 (VLGR1) and Its Regulation by PDZD7 Protein;Qiao-Xia Hu等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20140624;第289卷(第35期);第24215-24225页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108866102A (zh) | 2018-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107475300B (zh) | Ifit3-eKO1基因敲除小鼠动物模型的构建方法和应用 | |
CN106047930B (zh) | 一种PS1基因条件性敲除flox大鼠的制备方法 | |
CN108441520B (zh) | 利用CRISPR/Cas9系统构建的基因条件性敲除方法 | |
CN110551759B (zh) | 一种提高转基因细胞重组效率的组合物及方法 | |
CN108660161B (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
WO2017104404A1 (ja) | 遺伝子改変非ヒト生物、卵細胞、受精卵、及び標的遺伝子の改変方法 | |
CN108866102B (zh) | 一种Adgrv1基因Y6236fsX1突变动物模型的构建方法 | |
CN106282231B (zh) | 粘多糖贮积症ii型动物模型的构建方法及应用 | |
CN111926017A (zh) | 一种csf1ra基因缺失斑马鱼突变体的制备及其应用 | |
CN108893495B (zh) | 一种Pdzd7基因突变动物模型的构建方法 | |
CN110305896B (zh) | 一种斑马鱼肾脏祖细胞标记转基因系的构建方法 | |
CN110643636B (zh) | 一种团头鲂MSTNa&b基因敲除方法与应用 | |
CN113755498A (zh) | 靶向小鼠Ube3a基因的gRNA及构建AS疾病小鼠模型的方法 | |
CN113736787A (zh) | 靶向小鼠Atp7b基因的gRNA及构建Wilson疾病小鼠模型的方法 | |
CN109402170B (zh) | 一种鱼类雄性不育模型的建立方法 | |
CN111549070B (zh) | 对x染色体多拷贝基因进行编辑实现动物性别控制的方法 | |
CA3171406A1 (en) | Optimised methods for cleavage of target sequences | |
CN115807037B (zh) | 一种遗传可控的四倍体鱼的选育方法及三倍体鱼的制备方法 | |
CN113646429A (zh) | 敲入细胞的制作方法 | |
CN114934073B (zh) | hoxa1a基因敲除斑马鱼突变体的构建方法和应用 | |
CN113373150B (zh) | 一种靶向dat基因的sgRNA及其应用 | |
US20230257768A1 (en) | Poultry cell in which a gene encoding a protein of interest is knocked-in at egg white protein gene, and method for producing said poultry cell | |
CN113249409A (zh) | 一种bmi1基因缺失斑马鱼 | |
CN110218743B (zh) | 一种基于CRISPR/Cas9技术的牛磺酸转运体基因敲除大鼠模型的构建方法 | |
CN112695034A (zh) | ApoE基因缺失斑马鱼的制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |